JAZZ PHARMACEUTICALS PLC 2024-2025 Proxy Voting Records

Description as filed by funds: To elect four nominees for director named below to hold office until the 2027 Annual General Meeting of Shareholders: Kenneth W. O'Keefe

JAZZ PHARMACEUTICALS PLC’s own tally for this item (“Elect Director: Kenneth W. O'Keefe”): 50,931,857 for, 3,280,188 against, per its Form 8-K filed July 26, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Each of the four nominees for director was elected as follows:”
Support: 94% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 120 asset managers below reported 22,959,753 for, 236,488 against, 12,631 abstained.

Showing the 25 largest of 120 asset managers. See all 120 in the interactive database.

Description as filed by funds: To elect four nominees for director named below to hold office until the 2027 Annual General Meeting of Shareholders: Laura J. Hamill

JAZZ PHARMACEUTICALS PLC’s own tally for this item (“Elect Director: Laura J. Hamill”): 52,774,330 for, 1,432,999 against, per its Form 8-K filed July 26, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Each of the four nominees for director was elected as follows:”
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 120 asset managers below reported 23,194,845 for, 1,396 against, 12,631 abstained.

Showing the 25 largest of 120 asset managers. See all 120 in the interactive database.

Description as filed by funds: To elect four nominees for director named below to hold office until the 2027 Annual General Meeting of Shareholders: Mark D. Smith, M.D.

JAZZ PHARMACEUTICALS PLC’s own tally for this item (“Elect Director: Mark D. Smith, M.D.”): 50,507,449 for, 3,685,604 against, per its Form 8-K filed July 26, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Each of the four nominees for director was elected as follows:”
Support: 93% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 120 asset managers below reported 22,937,894 for, 258,347 against, 12,631 abstained.

Showing the 25 largest of 120 asset managers. See all 120 in the interactive database.

Description as filed by funds: To elect four nominees for director named below to hold office until the 2027 Annual General Meeting of Shareholders: Patrick Kennedy

JAZZ PHARMACEUTICALS PLC’s own tally for this item (“Elect Director: Patrick Kennedy”): 52,306,399 for, 1,901,706 against, per its Form 8-K filed July 26, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Each of the four nominees for director was elected as follows:”
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 120 asset managers below reported 23,194,845 for, 1,396 against, 12,631 abstained.

Showing the 25 largest of 120 asset managers. See all 120 in the interactive database.

Description as filed by funds: To grant the Board of Directors authority under Irish law to allot and issue ordinary shares for cash without first offering those ordinary shares to existing shareholders pursuant to the statutory pre- emption right that would otherwise apply.

JAZZ PHARMACEUTICALS PLC’s own tally for this item (“5. To grant our board of directors authority under Irish law to allot and issue ordinary shares for cash without first offering those ordinary shares to existing shareholders pursuant to the statutory pre-emption right t”): 52,568,310 for, 5,308,898 against — passed, per its Form 8-K filed July 26, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “This proposal was approved as follows: Proposal 5 Proposal 5 was to grant our board of directors authority under Irish law to allot and issue ordinary shares for cash without first offering those ordinary shares to existing shareholders pursuant to the statutory pre-emption right that would otherwi…”
Support: 91% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Also reported under other wordings, matched to the same row of JAZZ PHARMACEUTICALS PLC’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Authorise Issue of Equity without Pre-emptive Rights” (2 managers, 36,717 for).

The 119 asset managers below reported 22,172,268 for, 999,887 against.

Showing the 25 largest of 119 asset managers. See all 119 in the interactive database.

Description as filed by funds: To approve any motion to adjourn the Annual General Meeting, or any adjournments thereof, to another time and place to solicit additional proxies if there are insufficient votes at the time of the Annual General Meeting to approve Proposal 5.

The 118 asset managers below reported 21,672,583 for, 1,486,941 against, 12,631 abstained. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Showing the 25 largest of 118 asset managers. See all 118 in the interactive database.

Description as filed by funds: To approve, on a non-binding advisory basis, the compensation of Jazz Pharmaceuticals plc's named executive officers, as disclosed in the proxy statement.

JAZZ PHARMACEUTICALS PLC’s own tally for this item (“3. To approve, on a non-binding advisory basis, the compensation of our named executive officers as disclosed in the Proxy Statement”): 49,319,464 for, 4,780,265 against — passed, per its Form 8-K filed July 26, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “This proposal was approved as follows:”
Support: 91% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 119 managers: 23,017,069 for, 179,144 against, 12,631 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 435 managers: 29,789,996 for, 3,599,286 against, 142,874 abstained, 1,152 not voted, 101,034 1 year. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: To indicate, on a non-binding advisory basis, the preferred frequency of the advisory vote on the compensation of Jazz Pharmaceuticals plc's named executive officers.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Fund voting reports, all 116 managers: 22,122 for, 12,631 abstained, 21,804,296 1 year, 803,096 3 year. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 407 managers: 205,050 for, 93,787 abstained, 1,152 not voted, 30,595,912 1 year, 238,455 3 year, 35,939 2 year. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: To ratify, on a non-binding advisory basis, the appointment of KPMG as the independent auditors of Jazz Pharmaceuticals plc for the fiscal year ending December 31, 2024 and to authorize, in a binding vote, the Board of Directors, acting through the audit committee, to determine KPMG's remuneration.

JAZZ PHARMACEUTICALS PLC’s own tally for this item (“2. To ratify, on a non-binding advisory basis, the appointment of KPMG, Dublin as our independent auditors for the fiscal year ending December 31, 2024 and to authorize, in a binding vote, our board of directors, acting ”): 56,719,225 for, 1,184,200 against — passed, per its Form 8-K filed July 26, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “This proposal was approved as follows:”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 123 asset managers below reported 23,045,874 for, 149,013 against, 13,987 abstained.

Showing the 25 largest of 123 asset managers. See all 123 in the interactive database.